Tag Archives: tenofovir

Meta-analysis finds no real difference in safety and effectiveness between tenofovir formulations

There are no real differences between tenofovir formulations – tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) – in terms of viral suppression and bone and renal safety, according to a systematic review and meta-analysis published in AIDS. The newer formulation of the drug (TAF) only showed superiority in terms of efficacy, and then to a modest… Read More »

Doubt cast on link between tenofovir disoproxil and bone fractures

Treatment with tenofovir disoproxil fumarate (TDF) does not increase the risk of fractures, according to French research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Findings of the case-controlled study showed there was no association between tenofovir disoproxil and fractures in any of the statistical models designed by the authors.… Read More »